Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.91 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.91 |
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247170 | 0.94 | KCNK3 (0.91) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL14200525 | 0.89 | KCNK3 (0.73) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL4253897 | 0.89 | KCNK3 (0.93) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL3675463 | 0.89 | KCNK3 (0.84) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL3049631 | 0.86 | SMN1; SMN2 (0.79) | KCNK3KCNK9RAB9ANPC1 | |
| SCHEMBL21133083 | 0.86 | KCNK3 (0.86) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL8363018 | 0.86 | SMN1; SMN2 (0.76) | KCNK3KCNK9MEN1KMT2ARAB9A | |
| SCHEMBL259468 | 0.83 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL29434800 | 0.83 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL3786882 | 0.83 | KCNK3 (0.87) | KCNK3KCNK9MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442779-B2 | Compositions and methods for treating Friedreich's ataxia | FRATAGENE THERAPEUTICS S.R.L. (IT) | 2019-10-15 | — | — | US | disclosed |
| WO-2016046759-A2 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | FRATAGENE THERAPEUTICS LTD. (IT) | 2016-03-31 | — | — | WO | disclosed |
| US-20160083358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | FRATAGENE THERAPEUTICS S.R.L. (IT) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083358-A1 | COMPOSITIONS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN10, ATXN2, ATXN2L | KCNK3 2486/4885KCNK9 3144/4885MEN1 3654/4885 |
| US-10442779-B2 | Compositions and methods for treating Friedreich's ataxia | ATXN10, ATXN2, ATXN2L | KCNK3 2486/4885KCNK9 3144/4885MEN1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.